Search Results for “ oncology” – Page 14 – media

New policy review reveals ten cancer challenges facing new UK government

Macmillan Cancer Support estimates that cancer affects over three million people in the UK A new policy review produced by cancer doctors and experts from across the UK, including King’s College London (KCL), has revealed the ten biggest cancer challenges facing the new UK government. Published in the Lancet Oncology, the review highlights the time-critical issues impacting the delivery of cancer care services by the NHS, which should be urgently addressed via a comprehensive national cancer control plan. It is estimated that there are more than three million people living in the UK with cancer, according to Macmillan Cancer Support, with breast cancer being the most prevalent, accounting for more than 55,000 people. The authors said that the NHS in the UK is behind other countries and, if not prioritised, could add additional strain to the healthcare system, widen social inequality and weaken economic recovery. The review highlighted several ongoing ...
- Source: drugdu
- 72
- July 16, 2024
Dual HER2 Blockade Therapy Presented on MED and ESMO GI

Recently, results of the phase 2 study of HLX22, an innovative anti-HER2 monoclonal antibody (mAb), in combination with HANQUYOU (HLX02, trastuzumab, trade name: HERCESSI™️ in the U.S., Zercepac® in Europe) and chemotherapy for the first-line treatment of HER2-positive advanced gastric/gastroesophageal junction (G/GEJ) cancer were presented on 2024 ESMO Gastrointestinal Cancers Congress (ESMO GI) and MED, a flagship clinical and translational research monthly journal by Cell Press. The leading principal investigator for this study is Professor Jin Li from Shanghai East Hospital, School of Medicine, Tongji University. The results showed that the addition of HLX22 to HLX02 (trastuzumab) plus chemotherapy as first-line therapy improved efficacy in HER2-positive G/GEJ cancer patients with manageable safety. The results of HLX22-GC-201 were first presented at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI). The study data and updated results with another 7.8 months of follow-up were accepted for publication on MED ...
- Source: drugdu
- 64
- July 11, 2024
GSK Pays CureVac €400M to Pick Up Clinical-Stage mRNA Vaccines for Infectious Diseases

GSK is taking over development of an avian influenza vaccine candidate as a bird flu outbreak continues in U.S. dairy cows. Meanwhile, CureVac is restructuring and returning its attention to cancer vaccines, which was the initial focus of the mRNA company. By Frank VinluanGSK and CureVac forged their relationship during the Covid-19 pandemic, setting out to develop vaccines that could protect against the novel coronavirus and other infectious diseases. The collaboration has advanced two vaccine candidates into clinical testing, and now GSK is taking over both, one of them in development for an infectious disease target that’s particularly hot right now. Under terms of the restructured agreement announced Wednesday, GSK will now have full control of developing and manufacturing the avian influenza vaccine, currently in Phase 1 testing, and a Covid-19 vaccine in Phase 2 testing. GSK is paying €400 million (about $431.4 million) up front to obtain global rights ...
- Source: drugdu
- 92
- July 5, 2024
Advanced Blood Test Helps Improve Cancer Treatments

Early detection of cancer significantly increases the likelihood of successful treatment across various cancer types. In addition to personalized evaluation of therapy benefits and risks, continuous monitoring of treatment success is vital. Traditionally, oncologists rely on imaging technology and invasive procedures such as tissue biopsies, punctures, and endoscopic measures to monitor patients. Now, researchers have further developed an advanced method, a type of liquid biopsy that utilizes blood samples rather than direct tissue sampling for detecting various types of cancer. The technique, developed by researchers at the University of Zurich (UZH, Zurich, Switzerland) and the University Hospital Zurich (USZ, Zurich, Switzerland), involves sequencing and analyzing DNA fragments that circulate in the blood of patients to identify changes specific to particular cancers. The research team examined alterations in the number and length distribution of the DNA fragments, enabling them to distinguish between biologically less and more aggressive metastatic cancers even earlier ...
- Source: drugdu
- 102
- July 4, 2024
Female cancer survivors at low risk of developing obstetric complications

According to WHO, around 15% of pregnant women will develop an obstetric complication Researchers from the Universities of Birmingham, Bristol and Edinburgh have revealed that the majority of women who have survived cancer are at low risk of developing obstetric complications. The study published in the Lancet Oncology was funded by Children with Cancer UK, the Brain Tumour Charity and the Academy of Medical Sciences. Currently the most prevalent cancer in the UK, breast cancer affects around 55,000 women every year. According to the World Health Organization, around 15% of all pregnant women will develop a potentially life-threatening obstetric complication, including pyrexia and sepsis intrapartum haemorrhage, in pregnancy and childbirth and some will require a major obstetrical intervention to survive. After analysing data from almost 100,000 female survivors of cancer who had been diagnosed between the ages of 15 and 39 years between 1971 and 2006, approximately 21,437 births had ...
- Source: drugdu
- 102
- July 4, 2024
Henlius Receives Approval in Japan for Phase 3 MRCT of Anti-PD-1 mAb Serplulimab Combo on First-Line mCRC

Shanghai, China, July 2, 2024 – Shanghai Henlius Biotech, Inc. (2696.HK) announced that the clinical trial notification (CTN) for phase 3 international multicenter clinical study (ASTRUM-015) of Henlius’ self-developed anti-PD-1 monoclonal antibody (mAb) HANSIZHUANG (serplulimab) in combination with bevacizumab and chemotherapy in patients with metastatic colorectal cancer (mCRC) has been permitted by Japan’s Pharmaceuticals and Medical Devices Agency. The study has previously completed dosing of the first subject in China, and the regulatory registration and clinical development is advancing efficiently in more countries and regions around the world. Colorectal cancer (CRC) is one of the most common malignant cancers globally. Over 1.9 million newly diagnosed cases and more than 900,000 deaths were estimated in 2022, and the incidence rates were highest in Europe and Oceania [1]. It is estimated that, by 2040, the burden of CRC will increase to 3.2 million new cases per year (an increase of 63%) and ...
- Source: drugdu
- 80
- July 4, 2024
Hengrui’s Innovative Drug Henagliflozin Approved for New Indications, Providing New Treatment Options for Type 2 Diabetes Patients

Recently, Henagliflozin Pharmaceuticals received the Certificate of Drug Registration approved by the State Drug Administration, approving the new indication of Henagliflozin (Ruichin®), a Class 1 new drug, sodium-glucose cotransporter protein 2 inhibitor (SGLT2i) proline, which was independently researched and developed by the company: the product, 5mg or 10mg, combined with Regliflozin Phosphate and Metformin is used in patients with type 2 diabetes mellitus whose blood glucose is not yet reached after receiving Metformin monotherapy. adults with type 2 diabetes. This is the second indication for which Henagliflozin has been approved for marketing. Henagliflozin has thus become the only SGLT2i approved for combination therapy with dipeptidyl peptidase-IV inhibitors and metformin in China, which will provide a new therapeutic option for rational drug use in adult patients with type 2 diabetes mellitus. The approval of this indication for marketing is based on a multicenter, randomized, controlled, double-blind phase III clinical study [1]. ...
- Source: drugdu
- 128
- July 3, 2024
Novartis China President and Managing Director Leo Lee Joins PhRMA China Executive Liaison Group

The Pharmaceutical Research and Manufacturers of America (PhRMA) China Office announced that Mr. Leo Lee, President and Managing Director of Novartis China, has joined the PhRMA China Executive Liaison Group. Mr. Lee, a long-time veteran of the biopharmaceutical industry who has held senior management positions in a number of multinational corporations and has extensive experience in strategy development and implementation, business development and operational management, joins PhRMA’s China Executive Liaison Group and expresses its confidence that Mr. Lee will bring invaluable experience to the group, as well as its appreciation to the member companies for their continued support of PhRMA. Novartis is a member of the Pharmaceutical Research and Manufacturers of America (PhRMA). About the PhRMA China Executive Liaison Group The China Executive Liaison Group (CELG) consists of the China General Managers of PhRMA member companies. As an important bridge between PhRMA China Office and member companies in China, the ...
- Source: drugdu
- 89
- July 2, 2024
Sarclisa Combination Improves Progression-Free Survival in Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma

Don Tracy, Associate Editor Reportedly, data from the IMROZ study marks the first time an anti-CD38 monoclonal antibody combined with standard-of-care therapy has demonstrated significant improvement in progression-free survival for newly diagnosed transplant-ineligible multiple myeloma. Results from the IMROZ Phase III trial show that Sanofi’s Sarclisa (isatuximab-irfc) in combination with standard-of-care therapy comprised of lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death by 40% compared to a solo VRd regimen in patients with newly diagnosed transplant-ineligible multiple myeloma (MM). According to the company, the data represents the first time an anti-CD38 monoclonal antibody combined with VRdsupported a significant improvement in progression-free survival (PFS) for these patients. “The significant progression-free survival (PFS) benefit observed with Sarclisa combination therapy compared to VRd is important and encouraging for patients with newly diagnosed multiple myeloma. Effective frontline therapy has the potential to modify the course of the disease, which ...
- Source: drugdu
- 68
- July 1, 2024
TOFIDENCE (BAT1806/BIIB800), a biosimilar developed by BIO-THERA with reference to Amero® (tolizumab), received marketing approval from the European Commission.

BIO-THERA Biopharmaceutical Co., Ltd (SSE: 688177) is a global science-based and innovative biopharmaceutical company based in Guangzhou, China, hereinafter referred to as “BIO-THERA” or the “Company”. The Company is focused on developing a new generation of innovative drugs and biosimilars for the treatment of oncology, autoimmune diseases, cardiovascular diseases, ophthalmology and other major diseases that threaten human life or health. The Company’s partner, Bojian (NASDAQ: BIIB), recently received notification from the European Commission that it has granted marketing approval to BIO-THERA for the treatment of moderate to severe rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and other diseases. The approval follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in April 2024 for the treatment of moderate to severe rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and COVID-19. The European Commission’s approval of the marketing application for TOFIDENCE (BAT1806/BIIB800) ...
- Source: drugdu
- 67
- June 28, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.